Placentox Project: Environmental pollution and pregnancy: UMR-S767 Inserm/Paris Descartes . The Placentox project financed by the ANR studies the impact of benzopyrene on the development and hormonal functions of human placenta. If the toxic effects of this pollutant have been described in several organs, the mechanisms of its harmful action specifically at a placental level are unknown. This project has used the combination of two complementary approaches: analytical chemistry with mass spectrometry and the physiology of the human placenta (ex vivo perfusion and in vitro cultures). The application of the methodological approach used can also be used for the study of other environmental pollutants. The acquired data must now be integrated into the reflection on epidemiological studies. The scientific results will contribute to the implementation of recommendations on pregnant women’s environment, particularly in the National Plan for Health and Environment - PNSE3.
Melatonin Project (Premelip): Inserm AVENIR U676/R05230HS - Neonatal intensive care and paediatrics – R Debré, AP-HP. The therapeutic trial Premelip is a Phase IIB clinical trial begun in neonatal intensive care in March 2015 at the Robert Debré University Hospital Centre and the Créteil Intercommunal Hospital Centre. With Prof. O Baud’s team, we are studying the transplacental passage of melatonin in the human placental perfusion model.
Sickle-cell disease Project (DrO2G): Gynaecology and Obstetrics Hospital A Béclère, AP-HP. With Prof. A Benachi’s team, we are studying the impact of sickle-cell disease on placental function and pregnancy outcome and the effects of oxygen therapy. The DrO2G therapeutic trial is a phase III clinical trial begun by the Biotherapy department at Necker Hospital and the A Béclère Maternity Unit. The objective is to evaluate the efficacy of home administered prophylactic oxygen therapy during pregnancy, for women affected by sickle-cell disease, on the reduction of the number of vaso-occlusive crises. The aim of our study is also to evaluate the placental mechanisms responsible for the development of pre-eclampsia and IUGRs in sickle-cell patients and the effect of therapies (PhD research project).
APHERESE Project (Angiogenic switch to Physiological state by Extracorporeal Removal of sFlt1 and release of PlGF): consortium with the Pierre-Gilles Institute, Gennes (IPGG) also financed by the ANR. The objective of this project led by Prof. V Tsatsaris is to test a new therapeutic strategy against pre-eclampsia, aiming to re-establish physiological equilibrium between angiogenic factors in maternal blood, in order to improve the treatment of pre-eclamptic pregnancies and to reduce their consequences on prematurity. The study will provide pre-eclamptic maternal samples for the Perinat Collection.